Anti-EGFR, Recombinant [EGFR1]
Invented by Dr Peter Goodfellow from Abingworth Life Sciences
- References (2)
- Inventor Info
|Applications||FACS IHC IF IP WB|
|Antigen/Gene or Protein Targets||Epidermal Growth Factor Receptor (EGFR, Her1)|
Recombinant antibody which binds EGFR1 tyrosine kinase, commonly mutated in a range of cancers.
Background and Research Application
The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). EGFR activation signals multiple downstream signalling cascade pathways such as the Ras - ERK, PI3-K - Akt, Jak - STAT and PKC pathways which help in growth and proliferation of cells. Dysregulation of EGFR signalling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers, including head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, oesophagus, stomach and in squamous cell carcinoma. Tumours become dependent on EGFR signalling to maintain their malignant phenotypes.
This is a recombinant version of the anti-EGFR1 monoclonal antibody.
|Immunogen||Human epidermoid carcinoma line A431|
|Molecular Weight (kDa)||175|
|Research Area||Cancer, Cell Signaling & Signal Transduction|
|Immunogen UniProt ID||P00533|
Purified using multi-step affinity chromatography with protein A.
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.
Points of Interest
Anti-EGFR1 has no effect on tyrosine kinase activity of EGFR, and does not react with erbB-2, erbB-3 and erbB-4.
Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.
1mg/ml as standard
There are 2 reference entries for this reagent.View All References
Add an inventor